Journal
Pulmonary Circulation
Publication Date
4-1-2022
Volume
12
Issue
2
First Page
e12055
Document Type
Open Access Publication
DOI
10.1002/pul2.12055
Rights and Permissions
Rahaghi FF, Balasubramanian VP, Bourge RC, Burger CD, Chakinala MM, Eggert MS, Elwing JM, Feldman J, King C, Klinger JR, Mathai SC, McConnell JW, Palevsky HI, Restrepo-Jaramillo R, Safdar Z, Sager JS, Sood N, Sulica R, White RJ, Hill NS. Delphi consensus recommendation for optimization of pulmonary hypertension therapy focusing on switching from a phosphodiesterase 5 inhibitor to riociguat. Pulm Circ. 2022 Apr 7;12(2):e12055. doi: 10.1002/pul2.12055. © 2022 The Authors.Pulmonary Circulationpublished by John Wiley & Sons Ltd on behalf of Pulmonary Vascular Research Institute.
Recommended Citation
Rahaghi, Franck F; Balasubramanian, Vijay P; Bourge, Robert C; Burger, Charles D; Chakinala, Murali M; Eggert, Michael S; Elwing, Jean M; Feldman, Jeremy; King, Christopher; Klinger, James R; Mathai, Stephen C; McConnell, John Wesley; Palevsky, Harold I; Restrepo-Jaramillo, Ricardo; Safdar, Zeenat; Sager, Jeffrey S; Sood, Namita; Sulica, Roxana; White, R James; and Hill, Nicholas S, "Delphi consensus recommendation for optimization of pulmonary hypertension therapy focusing on switching from a phosphodiesterase 5 inhibitor to riociguat." Pulmonary Circulation. 12, 2. e12055 (2022).
https://digitalcommons.wustl.edu/open_access_pubs/12062
